This post was originally published on this site

In the last trading session, 1.53 million Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) shares changed hands as the company’s beta touched 2.46. With the company’s per share price at $4.47 changed hands at -$0.08 or -1.76% during last session, the market valuation stood at $187.70M. ZYNE’s last price was a discount, traded about -101.34% off its 52-week high of $9.00. The share price had its 52-week low at $3.15, which suggests the last value was 29.53% up since then. When we look at Zynerba Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 1.81 million shares, with the 3-month average coming to 1.60 million.

Analysts gave the Zynerba Pharmaceuticals Inc. (ZYNE) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ZYNE as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Zynerba Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$0.24.


3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Instantly ZYNE was in red as seen at the end of in last trading. With action -1.32%, the performance over the past five days has been red. The drop to weekly highs of 4.65 on Friday, 09/10/21 subtracted -1.76% to the stock’s daily price. The company’s shares are showing year-to-date upside of 35.45%, with the 5-day performance at -1.32% in the red. However, in the 30-day time frame, Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) is 1.59% up. Looking at the short shares, we see there were 2.33 million shares sold at short interest cover period of 1.3 days.

The consensus price target for the stock as assigned by Wall Street analysts is $7.17, meaning bulls need an upside of 37.66% from its current market value. According to analyst projections, ZYNE’s forecast low is $4.50 with $9.00 as the target high. To hit the forecast high, the stock’s price needs a -101.34% plunge from its current level, while the stock would need to soar -0.67% for it to hit the projected low.

Zynerba Pharmaceuticals Inc. (ZYNE) estimates and forecasts

Data shows that the Zynerba Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -5.10% over the past 6 months, a 43.68% in annual growth rate that is considerably higher than the industry average of 3.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Zynerba Pharmaceuticals Inc. will rise 69.20%, while the growth in revenue is estimated to hit 19.40% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.60%. The 2021 estimates are for Zynerba Pharmaceuticals Inc. earnings to decrease by -26.90%.

ZYNE Dividends

Zynerba Pharmaceuticals Inc. is expected to release its next quarterly earnings report between August 09 and August 13.

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.60% of Zynerba Pharmaceuticals Inc. shares while 32.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 33.10%. There are 32.24% institutions holding the Zynerba Pharmaceuticals Inc. stock share, with ETF Managers Group, LLC the top institutional holder. As of Mar 30, 2021, the company held 4.82% of the shares, roughly 1.99 million ZYNE shares worth $9.24 million.

AdvisorShares Investments, LLC holds the second largest percentage of outstanding shares, with 3.73% or 1.54 million shares worth $7.15 million as of Mar 30, 2021.

>> 7 Top Picks for the Post-Pandemic Economy <<

Among Mutual Funds, the top two as of Mar 30, 2021 were ETF Managers Tr-EFTMG Alternative Harvest ETF and Global X Fds-The Global X Cannabis ETF. With 1.99 million shares estimated at $9.24 million under it, the former controlled 4.82% of total outstanding shares. On the other hand, Global X Fds-The Global X Cannabis ETF held about 3.15% of the shares, roughly 1.3 million shares worth around $7.38 million.